Bellerophon Therapeutics: Funding, Investors & Team (Oct 2026)
Bellerophon Therapeutics LLC is a company that operates in the clinical stage biotherapeutics area, aiming to develop original treatments for cardiopulmonary and cardiac illnesses that are not adequately addressed by current therapies. Two of their product candidates are based on their own INOpulse® device, which provides pulsatile nitric oxide delivery. Currently, they are under Phase 2 clinical trials for treating PAH and PH-COPD. Moreover, the company has a third product candidate, named bioabsorbable cardiac matrix (BCM), which is an injectable device undergoing a feasibility clinical trial. This trial is comparable to a Phase 2 trial in U.S. drug development and is designed to determine the effectiveness of BCM in preventing cardiac remodeling and subsequent congestive heart failure following a heart attack, aiming to obtain a CE mark registration trial in the European Union.
Bellerophon Therapeutics has raised $5.0M across 1 funding round on record, the most recent an undisclosed round of $5.0M announced in Mar 2023.
That round is below the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Bellerophon Therapeutics Company Profile and Key Stats
Latest funding round on record: Mar 2023.
Bellerophon Therapeutics Funding Rounds
Bellerophon Therapeutics Founders and Leadership Team
Contact details for the Bellerophon Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Bellerophon Therapeutics Funding Compared to Other Biotechnology Startups
Bellerophon Therapeutics' latest round of $5.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Bellerophon Therapeutics in Biotechnology and Warren
Companies Similar to Bellerophon Therapeutics
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Bellerophon Therapeutics Funding FAQs
What does Bellerophon Therapeutics do?
Bellerophon Therapeutics LLC is a company that operates in the clinical stage biotherapeutics area, aiming to develop original treatments for cardiopulmonary and cardiac illnesses that are not adequately addressed by current therapies. Two of their product candidates are based on their own INOpulse® device, which provides pulsatile nitric oxide delivery. Currently, they are under Phase 2 clinical trials for treating PAH and PH-COPD. Moreover, the company has a third product candidate, named bioabsorbable cardiac matrix (BCM), which is an injectable device undergoing a feasibility clinical trial. This trial is comparable to a Phase 2 trial in U.S. drug development and is designed to determine the effectiveness of BCM in preventing cardiac remodeling and subsequent congestive heart failure following a heart attack, aiming to obtain a CE mark registration trial in the European Union.
How much funding has Bellerophon Therapeutics raised?
Bellerophon Therapeutics has raised $5.0M across 1 round on record. The most recent is an undisclosed round of $5.0M announced in Mar 2023.
When did Bellerophon Therapeutics last raise funding?
Bellerophon Therapeutics' most recent funding round on record is an undisclosed round of $5.0M, announced in Mar 2023.
Who is the CEO of Bellerophon Therapeutics?
Peter Fernandes is listed as CEO at Bellerophon Therapeutics.
Where is Bellerophon Therapeutics headquartered?
Bellerophon Therapeutics is based in Warren, New Jersey, United States.
How many employees does Bellerophon Therapeutics have?
Bellerophon Therapeutics is in the 11-50 employee band.
How does Bellerophon Therapeutics' funding compare to other Biotechnology startups?
Bellerophon Therapeutics' latest round of $5.0M is below the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Bellerophon Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Bellerophon Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.